

Appendix: Prophylaxis and Screening for Prevention of Respiratory Illness in Neonatal Intensive Care Unit Patients: A Systematic Review

A. Search Strategies and Results

A.1. Guideline Search Strategies (April 2011)

Table 1 Search of MEDLINE for Guidelines

#	Search History	Results
1	exp Respiratory Tract Infections/	244589
2	exp Virus Diseases/	599053
3	1 and 2	52335
4	exp Respiratory Syncytial Virus Infections/	3517
5	3 or 4	54539
6	limit 5 to (english language and humans and (guideline or practice guideline))	156
7	limit 6 to (systematic reviews)	130
8	limit 7 to (all infant (birth to 23 months))	61

Table 2 Search of Cochrane Library for Guidelines

#	Search History	Results
1	(virus diseases):ti,ab,kw and (respiratory tract infections):ti,ab,kw	153
2	(respiratory syncytial virus):ti,ab,kw	361
3	1 or 2, in Cochrane Reviews and Health Technology Assessments	25

Table 3 Search of National Guideline Clearinghouse (NGC) for Guidelines

Keyword	Results
respiratory viral infection	140
limit to infant age group	64

Table 4 Search of American Academy of Pediatrics (AAP) for Guideline

Search History	Results
Browsed http://pediatrics.aappublications.org/site/aappolicy/index.xhtml	49

Table 5 Search of Association for Professionals in Infection Control and Epidemiology (APIC) for Guidelines

Search History	Results
Browsed http://www.apic.org	3

Table 6 Search of CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) for Guidelines

Search History	Results
Browsed http://www.cdc.gov/hicpac	2

Table 7 Search of Infectious Diseases Society of America (IDSA) for Guidelines

Search History	Results
Browsed http://www.idsociety.org	1

Table 8 Search of National Institute for Health and Clinical Excellence (NICE) for Guidelines

Search History	Results
Browsed http://guidance.nice.org.uk	1

Table 9 Search of Scottish Intercollegiate Guidelines Network (SIGN) for Guidelines

Search History	Results
Browsed http://sign.ac.uk/guidelines/index.html	0

Table 10 Search of Society for Healthcare Epidemiology of America (SHEA) for Guidelines

Search History	Results
Browsed http://www.shea-online.org	1

A.2. Primary Study Search Strategies: Viral Respiratory Illnesses/ RSV

Table 11 Primary Viral Illness Search of MEDLINE

Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 11/18/2022
exp Intensive Care Units, Neonatal/ or exp Intensive Care, Neonatal/ OR Infant, Newborn/ AND (exp Respiratory Tract Infections/ AND exp Virus Diseases/) OR exp Respiratory Syncytial Virus Infections/ or exp Respiratory Syncytial Viruses/ AND exp Infection Control/ OR exp Cross Infection/ OR exp Communicable Disease Control/ NOT Exp Animals/ NOT exp humans/ AND publication dates English	341	158	631

Table 12 Primary Viral Illness Search of EMBASE

Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
(Exp respiratory tract infection/ and exp virus infection/) OR Exp respiratory syncytial virus infection/ OR exp respiratory syncytial pneumovirus/ AND Exp newborn intensive care/ or exp newborn/ AND Exp infection control/ or exp hospital infection/ or exp cross infection/ NOT Exp Animal/ NOT exp human/ AND publication dates English	16	9	52

Table 13 Primary Viral Illness Search of Cochrane Library

Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1. Intensive Care Units, Neonatal explode all trees 2. Intensive Care, Neonatal explode all trees 3. Infant, Newborn explode all trees 4. #1 OR #2 OR #3 5. "Respiratory Tract Infections" explode all trees 6. "Virus Diseases" explode all trees 7. #5 AND #6 8. "Respiratory Syncytial Virus Infections" explode all trees 9. #7OR #8 10. Infection Control explode all trees 11. Cross Infection explode all trees 12. Communicable Disease Control explode all trees 13. #10 OR #11 OR #12 14. #4 AND #9 AND #13 Publication date July 2016 -	71	12	4

Table 14 Primary Viral illness Search of CINAHL

Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
((MH "Virus Diseases+") AND (MH "Respiratory Tract Infections")) OR (MH "Respiratory Syncytial Virus Infections") OR (MH "Respiratory Syncytial Viruses") AND (MH "Intensive Care Units, Neonatal") OR (MH "Intensive Care, Neonatal") OR (MH "Infant, Newborn+") AND Limit to english language; exclude MEDLINE records; Published Date-	71	12	86

A.2. Primary Study Search Strategies: Varicella

Table 15 Primary Varicella Search of MEDLINE

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	exp Intensive Care Units, Neonatal/ or exp Intensive Care, Neonatal/	10468	15068	22079
2	exp Infant, Newborn/	440039	541022	655642
3	1 or 2	440773	542198	657262
4	exp Chickenpox/ or exp Herpesvirus 3, Human/	9087	11297	13218
5	3 and 4	758	893	974
6	exp Infection Control/	43472	55607	69291
7	exp Cross Infection/	39337	51355	63616
8	exp Communicable Disease Control/	207130	288187	395159
9	6 or 7 or 8	236616	326701	443885
10	5 and 9	95	123	156
11	limit 10 to (english language and humans)	79	108	139
12	(201607* OR 201608* OR 201609* OR 201610* OR 201611* OR 201612* OR 2017* OR 2018* OR 2019* OR 2020* OR 2021* OR 2022*).dt		22	28

Table 16 Primary Varicella Search of EMBASE

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	Exp newborn intensive care/ or exp newborn/	434871	351852	676874
2	Exp chickenpox/ or exp varicella zoster virus/	15108	16152	27589
3	1 and 2	647	538	966
4	Exp infection control/ or exp hospital infection/ or exp cross infection/	90076	120312	184646
5	3 and 4	29	28	35
6	Limit 5 to (english language and humans)	21	22	27

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
7	publication dates		4	1

Table 17 Primary Varicella Search of Cochrane Library

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	MeSH descriptor Intensive Care, Neonatal explode all trees	253	307	139
2	MeSH descriptor Intensive Care Units, Neonatal explode all trees	401	559	95
3	MeSH descriptor Infant, Newborn explode all trees	11218	14329	207
4	1 or 2 or 3	11250	14370	253
5	MeSH descriptor Cross Infection explode all trees	1277	1477	1392
6	MeSH descriptor Infection Control explode all trees	1080	1293	1631
7	MeSH descriptor Communicable Disease Control explode all trees	3811	5096	72
8	5 or 6 or 7	4796	6267	1713
9	4 and 8	366	478	150
10	MeSH descriptor Chickenpox explode all trees	154	139	3
11	MeSH descriptor Herpesvirus 3, Human explode all trees	116	133	10
12	10 or 11	223	226	12
13	9 and 12	6	3	3
14	Limit to 2016-current		1	3

Table 18 Primary Varicella Search of CINAHL

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	(MH "Intensive Care, Neonatal+") or (MH "Intensive Care Units, Neonatal")	6428	10033	19863
2	(MH "Chickenpox") or (MH "Herpesviruses+")	2160	3144	8287
3	MH "Infection Control+"	29526	42696	80711
4	MH "Cross Infection+"	14160	21838	34914
5	MH "Communicable Diseases"	4254	5884	12383
6	3 or 4 or 5	40673	59588	112404
7	MH "Infant, Newborn+"	49610	66361	152560
8	1 or 7	50951	69458	157914
9	2 and 6 and 8	29	37	63
10	Limit to publication dates		3	13

A.2. Primary Study Search Strategies: Pertussis

Table 19 Primary Pertussis Search of MEDLINE

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	exp Intensive Care Units, Neonatal/ or exp Intensive Care, Neonatal/	10468	15068	22079
2	exp Infant, Newborn/	440039	541022	655642
3	1 or 2	440773	542198	657262
4	exp Infection Control/	43472	55607	69291
5	exp Cross Infection/	39337	51355	63616
6	exp Communicable Disease Control/	207130	288187	395159
7	4 or 5 or 6	236616	326701	443885
8	exp Whooping Cough/	5724	7591	8996
9	exp Bordetella/ or exp Bordetella Infections/ or exp Bordetella pertussis/	9661	11920	13711
10	8 or 9	9661	11920	13711
11	3 and 7 and 10	237	362	533
12	limit 11 to (english language and humans)	177	292	450
13	publication year		93	142

Table 20 Primary Pertussis Search of EMBASE

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	Exp newborn intensive care/ or exp newborn/	434871	351852	676874
2	Exp bordetella pertussis/ or exp pertussis/	12291	11227	22518
3	Exp infection control/ or exp hospital infection/ or exp cross infection/	90076	120312	184646
4	1 and 2	634	561	1204
5	3 and 4	41	45	56
6	Limit 5 to (english language and humans)	31	38	44
7	publication year		7	2

Table 21 Primary Pertussis Search of Cochrane Library

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	MeSH descriptor Intensive Care, Neonatal explode all trees	253	307	139
2	MeSH descriptor Intensive Care Units, Neonatal explode all trees	401	559	95
3	MeSH descriptor Infant, Newborn explode all trees	11218	14329	207
4	1 or 2 or 3	11250	14370	253
5	MeSH descriptor Cross Infection explode all trees	1277	1477	1392

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
6	MeSH descriptor Infection Control explode all trees	1080	1293	1631
7	MeSH descriptor Communicable Disease Control explode all trees	3811	5096	72
8	5 or 6 or 7	4796	6267	1713
9	4 and 8	366	478	150
10	MeSH descriptor Bordetella pertussis explode all trees	116	118	5
11	MeSH descriptor Whooping Cough explode all trees	203	221	10
12	MeSH descriptor Bordetella explode all trees	117	119	6
13	MeSH descriptor Bordetella Infections explode all trees	203	221	6
14	10 or 11 or 12 or 13	255	274	12
15	9 and 14	4	8	5
16	Publication Year		2	3

Table 22 Primary Pertussis Search of CINAHL

#	Search History	Results through 12/2012	Results 12/2012 - 7/5/2016	Results 7/5/2016 – 11/18/2022
1	(MH "Intensive Care, Neonatal+") or (MH "Intensive Care Units, Neonatal") or (MH "Infant, Newborn+")	50951	72510	157914
2	(MH "Bordetella Pertussis") or (MH "Whooping Cough")	707	1186	2160
3	MH "Infection Control+"	29526	42696	80711
4	MH "Cross Infection+"	14160	21838	34914
5	MH "Communicable Diseases"	4254	5884	12383
6	3 or 4 or 5	40673	59588	112404
7	1 and 2 and 6	41	77	134
8	Limit 7 to (english language; exclude MEDLINE records)	10	19	37
9	Limit to year		8	11

B. Study Exclusion Criteria

Criteria for excluding studies from the literature review are:

1. Not relevant to key questions
2. Not primary research
3. Meeting abstract only
4. No full text available
5. Not in English

6. Not 100% of patients are in NICU patients
7. Mixed patient population without NICU subgroups or infant location not specified
8. Methods paper on HAI surveillance only
9. Exclude studies examining interventions of any kind (single or multi-intervention) unless they provide a clear description of the interventions and statistical analysis comparing time points before and after the intervention
10. N<10 exposed
11. Study only examining immunizations
12. Other

C. Evidence Review

Question 1. In neonatal intensive care unit patients, does prophylaxis after viral exposure (e.g., palivizumab, oseltamivir), compared to no prophylaxis, prevent the transmission of infection?

Question 2. In neonatal intensive care unit patients, does prophylactic administration of palivizumab, compared with no palivizumab, prevent the transmission of RSV during RSV season?

Question 3. In neonatal intensive care unit patients, does prophylactic administration of palivizumab, compared to no palivizumab, prevent the transmission of RSV during an RSV outbreak?

No evidence was retrieved that answered these questions for NICU patients.

D. References for Select Excluded Studies

1. Preterm Infants Face High RSV Risk. *AACN Bold Voices*. 2017;9(9):15-15.
2. Immunoprophylaxis Urged to Halt RSV. *Neonatal Intensive Care*. 2017;30(4):10-11.
3. RSV Trial Reaches Milestone. *Neonatal Intensive Care*. 2018;31(3):5-6.
4. Anderson EJ, DeVincenzo JP, Simões EAF, et al. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. *American Journal of Perinatology*. 2020;37(4):421-429. doi:10.1055/s-0039-1681014
5. Anderson EJ, McBride SJ, McLaurin KK, et al. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis. *American Journal of Perinatology*. 2017;34(1):51-61. doi:10.1055/s-0036-1584147
6. Boyce TG, Yogev R, DeVincenzo JP, Krilov LR, Farber HJ. Confounding by Indication Limits Conclusions of Study of Palivizumab Effectiveness...Farber HJ, Buckwold FJ, Lachman B, et al. Observed effectiveness of palivizumab for 29-36-week gestation infants. *Pediatrics*. 2016;138(2):e20160627. Chicago, Illinois: American Academy of Pediatrics; 2017. p. 1-2.
7. Byington CL, Munoz FM. Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines. Chicago, Illinois: American Academy of Pediatrics; 2016. p. 1-3.
8. Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi GA, Sacco O. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. *Italian Journal of Pediatrics*. 2017;43:1-5. doi:10.1186/s13052-017-0390-8
9. Cavicchiolo ME, Lolli E, Trevisanuto D, Baraldi E. Managing a tertiary-level NICU in the time of COVID-19: Lessons learned from a high-risk zone. *Pediatric Pulmonology*. 2020;55(6):1308-1310.
10. Cutrera R, Wolfler A, Picone S, et al. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports. *Italian Journal of Pediatrics*. 2019;45(1):N.PAG-N.PAG. doi:10.1186/s13052-019-0736-5
11. de Souza RP, Ribeiro ALR, de Menezes SAF, Machado LFA. Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Para state, north region of Brazil. *BMC Pediatrics*. 2019;19(1):299.
12. French CE, McKenzie BC, Coope C, et al. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. *Influenza and other Respiratory Viruses*. 2016;10(4):268-290.

13. Gortner L. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. *Klinische Padiatrie*. 2017;229(5):259-260.
14. Gortner L. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. *Klinische Padiatrie*. 2017;229(5):259-260. doi:<http://dx.doi.org/10.1055/s-0043-116334>
15. Grant CC, Huang QS, Trenholme A, Taylor S, Wood T. What can we learn from our 2021 respiratory syncytial virus experience? *New Zealand Medical Journal*. 2021;134(1540):7-12.
16. Kong AM, Krilov LR, Fergie J, et al. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States. *American Journal of Perinatology*. 2018;35(2):192-200. doi:10.1055/s-0037-1606352
17. Krilov LR, Anderson EJ. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics. *Journal of Perinatology*. 2020;40(8):1135-1144. doi:10.1038/s41372-020-0689-y
18. Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants. *American Journal of Perinatology*. 2020;37(2):174-183. doi:10.1055/s-0039-1694008
19. Mac S, Sumner A, Duchesne-Belanger S, Stirling R, Tunis M, Sander B. Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. *Pediatrics*. 2019;143(5):1-21. doi:10.1542/peds.2018-4064
20. Maeda H, Haneda K, Honda Y. Parainfluenza virus type 3 outbreak in a neonatal intensive care unit. *Pediatrics International*. 2017;59(11):1219-1222. doi:10.1111/ped.13389
21. Marcone DN, Carballal G, Iraneta M, Rubies Y, Vidaurreta SM, Echavarria M. Nosocomial Transmission and Genetic Diversity of Rhinovirus in a Neonatal Intensive Care Unit. *Journal of Pediatrics*. 2018;193:252-255.e1. doi:<https://dx.doi.org/10.1016/j.jpeds.2017.09.013>
22. McLaurin KK, Farr AM, Wade SW, Diakun DR, Stewart DL. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants. *Journal of Perinatology*. 2016;36(11):990-996. doi:10.1038/jp.2016.113
23. McRae JE, Blyth CC, Cheng AC, et al. Risk factors and disease severity in Australian infants aged under 6 months hospitalised with influenza 2011-2019. *Journal of Paediatrics & Child Health*. 2022;58(5):848-855. doi:<https://dx.doi.org/10.1111/jpc.15857>
24. Mermel LA, Jefferson JA, Smit MA, Auld DB. Prevention of hospital-acquired respiratory viral infections: Assessment of a multimodal intervention program. *Infection Control & Hospital Epidemiology*. 2019;40(3):362-364. doi:<https://dx.doi.org/10.1017/ice.2018.337>
25. Ng PC. Infection Control Measures for COVID-19 in the Labour Suite and Neonatal Unit. *Neonatology*. 2020;117(2):141-143. doi:<https://dx.doi.org/10.1159/000508002>
26. Ozkan H, Celebi S, Koksall N, et al. Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study. *American Journal of Perinatology*. 2021;38(14):1540-1546. doi:10.1055/s-0040-1713928
27. Poole CL, Camins BC, Prichard MN, Faye-Petersen O, Hutto C. Hospital-acquired viral respiratory infections in neonates hospitalized since birth in a tertiary neonatal intensive care unit. *Journal of Perinatology*. 2019;39(5):683-689. doi:<https://dx.doi.org/10.1038/s41372-019-0318-9>
28. Priante E, Mardegan V, Tavella E, et al. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study. *American Journal of Perinatology*. 2019;36:S77-S82. doi:10.1055/s-0039-1691771
29. Raguz MJ, Brzica J, Grgic I. Palivizumab: The Effects of Prophylactic Immunization on the Occurrence of Infections Caused by the Respiratory Syncytial Virus. *Klinische Padiatrie*. 2017;229(5):281-285. doi:<https://dx.doi.org/10.1055/s-0043-112499>
30. Rose EB, Washington EJ, Wang L, et al. Multiple Respiratory Syncytial Virus Introductions Into a Neonatal Intensive Care Unit. *Journal of the Pediatric Infectious Diseases Societ*. 2021;10(2):118-124. doi:<https://dx.doi.org/10.1093/jpids/piaa026>
31. Saiman L, Acker KP, Dumitru D, et al. Infection prevention and control for labor and delivery, well baby nurseries, and neonatal intensive care units. *Seminars in Perinatology*. 2020;44(7):151320. doi:<https://dx.doi.org/10.1016/j.semperi.2020.151320>

32. Shui JE, Messina M, Hill-Ricciuti AC, et al. Impact of respiratory viruses in the neonatal intensive care unit. *Journal of Perinatology*. 2018;38(11):1556-1565. doi:10.1038/s41372-018-0197-5
33. Simões EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants. *Clinical Infectious Diseases*. 2021;73(11):e4400-e4408. doi:10.1093/cid/ciaa951
34. Washington EJ, Rose EB, Langley GE, et al. Notes from the Field: Respiratory Syncytial Virus Infections in a Neonatal Intensive Care Unit - Louisiana, December 2017. *MMWR - Morbidity & Mortality Weekly Report*. 2019;68(1):20-21. doi:<https://dx.doi.org/10.15585/mmwr.mm6801a5>